CG Oncology Inc. Common s... (CGON)
CG Oncology Common stock Statistics
Share Statistics
CG Oncology Common stock has 76.22M shares outstanding. The number of shares has increased by 15.29% in one year.
| Shares Outstanding | 76.22M |
| Shares Change (YoY) | 15.29% |
| Shares Change (QoQ) | 0.92% |
| Owned by Institutions (%) | 98.63% |
| Shares Floating | 46.04M |
| Failed to Deliver (FTD) Shares | 190 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 6.37M, so 8.37% of the outstanding shares have been sold short.
| Short Interest | 6.37M |
| Short % of Shares Out | 8.37% |
| Short % of Float | 12.7% |
| Short Ratio (days to cover) | 7.17 |
Valuation Ratios
The PE ratio is -20.36 and the forward PE ratio is -15.72. CG Oncology Common stock's PEG ratio is -0.22.
| PE Ratio | -20.36 |
| Forward PE | -15.72 |
| PS Ratio | 1573.67 |
| Forward PS | 1.9 |
| PB Ratio | 2.44 |
| P/FCF Ratio | -22.7 |
| PEG Ratio | -0.22 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for CG Oncology Common stock.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 35.3, with a Debt / Equity ratio of 0.
| Current Ratio | 35.3 |
| Quick Ratio | 35.3 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $10.08K |
| Profits Per Employee | $-779.11K |
| Employee Count | 113 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -41.7% in the last 52 weeks. The beta is 1.24, so CG Oncology Common stock's price volatility has been higher than the market average.
| Beta | 1.24 |
| 52-Week Price Change | -41.7% |
| 50-Day Moving Average | 27.54 |
| 200-Day Moving Average | 32.43 |
| Relative Strength Index (RSI) | 30.94 |
| Average Volume (20 Days) | 655.89K |
Income Statement
In the last 12 months, CG Oncology Common stock had revenue of 1.14M and earned -88.04M in profits. Earnings per share was -1.41.
| Revenue | 1.14M |
| Gross Profit | 1.14M |
| Operating Income | -114.67M |
| Net Income | -88.04M |
| EBITDA | -114.67M |
| EBIT | -114.67M |
| Earnings Per Share (EPS) | -1.41 |
Balance Sheet
The company has 257.07M in cash and 238K in debt, giving a net cash position of 256.83M.
| Cash & Cash Equivalents | 257.07M |
| Total Debt | 238K |
| Net Cash | 256.83M |
| Retained Earnings | -217.98M |
| Total Assets | 754.8M |
| Working Capital | 732.84M |
Cash Flow
In the last 12 months, operating cash flow was -78.71M and capital expenditures -234K, giving a free cash flow of -78.95M.
| Operating Cash Flow | -78.71M |
| Capital Expenditures | -234K |
| Free Cash Flow | -78.95M |
| FCF Per Share | -1.26 |
Margins
Gross margin is 100%, with operating and profit margins of -10067.25% and -7729.5%.
| Gross Margin | 100% |
| Operating Margin | -10067.25% |
| Pretax Margin | -7729.5% |
| Profit Margin | -7729.5% |
| EBITDA Margin | -10067.25% |
| EBIT Margin | -10067.25% |
| FCF Margin | -6931.26% |
Dividends & Yields
CGON does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CGON is $65, which is 190.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $65 |
| Price Target Difference | 190.4% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | 52.97 |
| Piotroski F-Score | 5 |